Why the study?
Do stem cells or progenitor cells improve outcomes in patients with ischemic heart disease and heart failure?
Do stem cells or progenitor cells improve outcomes in patients with ischemic heart disease and heart failure?
This review highlights two decades of progress in stem cell therapy for ischemic heart disease and heart failure, demonstrating potential benefits in cardiac function and symptoms with few adverse effects.
Advances in the novel approach to control ischemic heart disease and heart failure using stem cells or progenitor cells from bone marrow, mesenchyme, or myocardial tissue itself have demonstrated efficacy for increasing left ventricular function, decreasing infarct scar tissue, improving exercise tolerance and heart failure symptoms, and, in some studies, decreasing mortality and reducing rehospitalization for intractable angina or subsequent myocardial infarction. The most common techniques utilize injections of cells into the coronary vasculature or directly into specific areas of vulnerable myocardium. Although few adverse effects have been noted in clinical trials of these procedures, further clinical trials over the next decade should provide further advances in interventional techniques, ancillary supporting technologies to enhance cell regeneration, and applications in ischemic heart disease, cardiomyopathies, and cardiac genetic disorders.
No takes yet. Share an insight, caveat, or question.
Philip R. Liebson (2015) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: